Akero Therapeutics, Inc. (AKRO)
NASDAQ
Market Cap
$1.74B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
524 of 954
Rank in Industry
284 of 546
Largest Insider Buys in Sector
AKRO Stock Price History Chart
AKRO Stock Performance
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Activity of Akero Therapeutics, Inc.
Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $0 and sold $25.61M worth of Akero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $30.9M and sold $40.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $1.98M was made by Graham G. Walmsley (director) on 2023‑12‑08.
List of Insider Buy and Sell Transactions, Akero Therapeutics, Inc.
| 2025-01-02 | Sale | Chief Operating Officer | 10,000 0.0144% | $28.03 | $280,330 | -1.57% | ||
| 2024-12-17 | Sale | Chief Scientific Officer | 3,800 0.0055% | $31.10 | $118,172 | -8.00% | ||
| 2024-12-16 | Sale | Chief Development Officer | 9,074 0.013% | $29.11 | $264,117 | -3.39% | ||
| 2024-12-16 | Sale | Senior VP, Commercial Strategy | 1,000 0.0014% | $29.13 | $29,130 | -3.39% | ||
| 2024-12-10 | Sale | President and CEO | 7,855 0.0114% | $30.79 | $241,855 | -7.41% | ||
| 2024-12-10 | Sale | Chief Operating Officer | 2,503 0.0036% | $30.79 | $77,067 | -7.41% | ||
| 2024-12-10 | Sale | Chief Scientific Officer | 4,818 0.007% | $30.91 | $148,934 | -7.41% | ||
| 2024-12-10 | Sale | Chief Development Officer | 2,810 0.0041% | $30.79 | $86,520 | -7.41% | ||
| 2024-12-10 | Sale | Chief Financial Officer | 2,817 0.0041% | $30.79 | $86,735 | -7.41% | ||
| 2024-12-10 | Sale | Senior VP, Commercial Strategy | 925 0.0013% | $30.79 | $28,481 | -7.41% | ||
| 2024-12-02 | Sale | President and CEO | 25,000 0.0358% | $32.09 | $802,250 | -9.31% | ||
| 2024-12-02 | Sale | Chief Operating Officer | 10,000 0.0143% | $32.13 | $321,310 | -9.31% | ||
| 2024-11-15 | Sale | Chief Development Officer | 9,061 0.0122% | $27.73 | $251,274 | +8.05% | ||
| 2024-11-06 | Sale | Chief Development Officer | 10,000 0.0143% | $35.19 | $351,890 | -13.15% | ||
| 2024-11-01 | Sale | President and CEO | 108,366 0.1532% | $31.73 | $3.44M | -5.23% | ||
| 2024-11-01 | Sale | Chief Operating Officer | 50,716 0.0713% | $31.57 | $1.6M | -5.23% | ||
| 2024-11-01 | Sale | Chief Development Officer | 15,485 0.0225% | $32.62 | $505,105 | -5.23% | ||
| 2024-10-30 | Sale | Chief Development Officer | 4,515 0.0069% | $32.53 | $146,855 | +0.16% | ||
| 2024-10-18 | Sale | President and CEO | 63,539 0.0924% | $31.53 | $2M | -1.41% | ||
| 2024-10-17 | Sale | President and CEO | 3,103 0.0045% | $31.12 | $96,559 | +0.03% |
Insider Historical Profitability
6%
| Cheng Andrew | President and CEO | 597562 0.8561% | $24.89 | 0 | 39 | |
| Young Jonathan | Chief Operating Officer | 218083 0.3124% | $24.89 | 0 | 34 | |
| Rolph Timothy | Chief Scientific Officer | 178337 0.2555% | $24.89 | 0 | 18 | |
| Yale Catriona | Chief Development Officer | 95648 0.137% | $24.89 | 0 | 36 | |
| White William Richard | Chief Financial Officer | 38335 0.0549% | $24.89 | 0 | 26 | |
| Lamy Patrick | Senior VP, Commercial Strategy | 34258 0.0491% | $24.89 | 0 | 3 | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 5830203 8.3528% | $24.89 | 2 | 0 | <0.0001% |
| Skorpios Trust | director | 3271829 4.6875% | $24.89 | 0 | 1 | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 3092698 4.4309% | $24.89 | 1 | 22 | +13.18% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3033552 4.3461% | $24.89 | 1 | 25 | +13.18% |
| Graham G. Walmsley | director | 800000 1.1461% | $24.89 | 9 | 0 | +9.4% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 505099 0.7236% | $24.89 | 1 | 0 | +13.18% |
| Royston Aaron | director | 250000 0.3582% | $24.89 | 1 | 0 | +13.18% |
| Harrison Seth Loring | director | 136301 0.1953% | $24.89 | 2 | 5 | <0.0001% |
| Henderson Jane | director | 0 0% | $24.89 | 0 | 1 | |
| Bitterman Kevin | director | 0 0% | $24.89 | 1 | 2 | +13.18% |
| Heyman Tomas J. | director | 0 0% | $24.89 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Janus Henderson | $154.59M | 8.85 | 6.12M | +42.16% | +$45.85M | 0.08 | |
| RTW Investments, LP | $137.21M | 7.86 | 5.43M | +51.19% | +$46.46M | 2.06 | |
| General Atlantic | $132.21M | 7.57 | 5.23M | +193.1% | +$87.1M | 3.44 | |
| Wellington Management Company | $131.69M | 7.54 | 5.21M | +80.89% | +$58.89M | 0.02 | |
| BlackRock | $123.59M | 7.08 | 4.89M | +17.03% | +$17.99M | <0.01 | |
| T. Rowe Price | $102.57M | 5.87 | 4.06M | +10.46% | +$9.71M | 0.01 | |
| State Street | $95.93M | 5.49 | 3.8M | -25.87% | -$33.47M | <0.01 | |
| The Vanguard Group | $92.7M | 5.31 | 3.67M | +18.96% | +$14.77M | <0.01 | |
| Alkeon Capital Management Llc | $84.05M | 4.81 | 3.33M | -11.61% | -$11.04M | 0.46 | |
| Baker Bros Advisors LP | $68.54M | 3.92 | 2.71M | +14.56% | +$8.71M | 0.49 | |
| Redmile Group | $46.95M | 2.69 | 1.86M | +67.53% | +$18.93M | 0.48 | |
| Boxer Capital, LLC | $42.35M | 2.42 | 1.68M | 0% | +$0 | 0.87 | |
| AllianceBernstein | $40.95M | 2.35 | 1.62M | +0.84% | +$342,803.46 | 0.01 | |
| Yiheng Capital Llc | $36.23M | 2.07 | 1.43M | -25.45% | -$12.36M | 5.28 | |
| Geode Capital Management | $35.86M | 2.05 | 1.42M | +21.7% | +$6.39M | <0.01 | |
| Perceptive Advisors | $35.05M | 2.01 | 1.39M | +43.37% | +$10.6M | 0.02 | |
| Alger | $33.77M | 1.93 | 1.34M | +1,372.14% | +$31.48M | 0.17 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $32.84M | 1.88 | 1.3M | +20.24% | +$5.53M | 0.86 | |
| T Rowe Price Investment Management Inc | $27.84M | 1.59 | 1.1M | New | +$27.84M | 0.02 | |
| Logos Global Management Lp | $20.21M | 1.16 | 800,000 | 0% | +$0 | 2.18 | |
| Millennium Management LLC | $20.02M | 1.15 | 792,575 | +208.16% | +$13.52M | 0.01 | |
| Schonfeld Group | $17.57M | 1.01 | 695,723 | +417.84% | +$14.18M | 0.1 | |
| Northern Trust | $15.1M | 0.86 | 597,688 | +10.54% | +$1.44M | <0.01 | |
| Goldman Sachs | $14.9M | 0.85 | 589,852 | -3.82% | -$591,665.00 | <0.01 | |
| Emerald Advisers, Inc. | $13.61M | 0.78 | 538,873 | +285.76% | +$10.08M | 0.55 | |
| Charles Schwab | $13.09M | 0.75 | 518,286 | +21.79% | +$2.34M | <0.01 | |
| Bank of America | $10.76M | 0.62 | 425,871 | -13.02% | -$1.61M | <0.01 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $10.73M | 0.61 | 424,901 | +266.04% | +$7.8M | 0.56 | |
| Citadel Advisors LLC | $10.6M | 0.61 | 419,660 | -13.48% | -$1.65M | 0.01 | |
| D. E. Shaw & Co. | $10.28M | 0.59 | 407,125 | +92.99% | +$4.96M | 0.01 | |
| Morgan Stanley | $10.2M | 0.58 | 403,863 | -61.8% | -$16.51M | <0.01 | |
| Silverarc Capital Management Llc | $10.1M | 0.58 | 399,949 | +60.46% | +$3.81M | 0.1 | |
| Octagon Capital Advisors LP | $8.59M | 0.49 | 340,000 | New | +$8.59M | 0.05 | |
| Bioimpact Capital Llc | $8.41M | 0.48 | 332,924 | New | +$8.41M | 1.36 | |
| Long Focus Capital Management Llc | $8.3M | 0.48 | 328,604 | -35.57% | -$4.58M | 0.98 | |
| Deutsche Bank | $8.25M | 0.47 | 326,755 | +71.79% | +$3.45M | <0.01 | |
| JPMorgan Chase | $8.22M | 0.47 | 325,399 | +112.85% | +$4.36M | <0.01 | |
| Artisan Partners | $7.68M | 0.44 | 303,920 | 0% | +$0 | 0.01 | |
| Rafferty Asset Management Llc | $7.43M | 0.43 | 294,113 | -34.91% | -$3.98M | 0.02 | |
| Point72 Asset Management | $7.3M | 0.42 | 289,106 | -55.13% | -$8.97M | 0.01 | |
| Citigroup | $6.45M | 0.37 | 255,434 | +35.54% | +$1.69M | 0.01 | |
| Jane Street Capital | $6.32M | 0.36 | 250,075 | -2.14% | -$138,273.23 | 0.01 | |
| Simplify Asset Management Inc | $6.21M | 0.36 | 245,676 | +310.99% | +$4.7M | 0.6 | |
| Candriam S C A | $6.06M | 0.35 | 240,000 | +30.43% | +$1.41M | 0.04 | |
| Ensign Peak Advisors Inc | $5.87M | 0.34 | 232,544 | -0.31% | -$18,187.20 | 0.01 | |
| UBS | $5.25M | 0.3 | 208,001 | -21.92% | -$1.47M | <0.01 | |
| Standard Life | $5.03M | 0.29 | 199,237 | +178.49% | +$3.23M | 0.01 | |
| BNY Mellon | $4.78M | 0.27 | 189,246 | +6.44% | +$289,252.38 | <0.01 | |
| Schroder Investment Management Group | $4.32M | 0.25 | 170,956 | New | +$4.32M | 0.01 | |
| Sphera Fund | $4.05M | 0.23 | 160,445 | New | +$4.05M | 0.03 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.